ANALYSIS OF RAAS BIOMARKERS TO CLASSIFY ANTI-HYPERTENSIVE DRUG TREATMENTS IN THE GENERAL POPULATION: THE CHRIS STUDY. Arisido MW, Foco L, Gogele M, Melotti R, et al. J Hypertens 2022;40.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Arisido MW, Foco L, Gogele M, Melotti R, et al. ANALYSIS OF RAAS BIOMARKERS TO CLASSIFY ANTI-HYPERTENSIVE DRUG TREATMENTS IN THE GENERAL POPULATION: THE CHRIS STUDY. J Hypertens 2022;40.
PMID: 36026761